Allergy

>

Latest News

ARS Pharma Submits Response to FDA Complete Response Letter for neffy (epinephrine nasal spray) / image credit word map anaphylaxis ©kalpis/stock.adobe.com
ARS Pharma Submits Response to FDA Complete Response Letter for neffy (epinephrine nasal spray)

April 3rd 2024

Positive findings from a repeat dosing study of neffy under nasal allergen challenge conditions will support a potential PDUFA date of October 2, 2024, the company said.

Clinical Focus Business Focus Spotlight TGIF for Optinose Xhance: PDUFA Date Set for Saturday, March 16, 2024 / image credit nasal passages: ©turhanerbas/stock.adobe.com
Optinose Xhance approved by FDA as first medical therapy for CRS

March 15th 2024

Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose / image credit: ©New Africa/AdobeStock
Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose

March 7th 2024

Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers / image credit: epipen injection: ©Rob Byron/stock.adobe.com
Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers

February 27th 2024

New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares / Image credit: ©chomplearn 2001/AdobeStock
New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares

February 26th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.